Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell’epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0–F2
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
A recent meta-analysis pointed out that pegylated interferon α-2a is more effective than peginterferon α-2b in terms of rapid virological response (RVR) in the treatment of chronic hepatitis C (CHC). Considering the availability of triple therapy (TT—pegylated interferon, ribavirin and protease inhibitor) and the possibility to follow different treatment algorithms based on RVR achievement, verified after a 4 week lead-in period of dual therapy (DT—pegylated interferon and ribavirin), rational decisions, taking into account also economic implications, become particularly important, especially in a healthcare cost containment context.
To compare the overall treatment cost in function of the decision to start the DT 4 week lead-in period with pegylated interferon α-2a plus ribavirin or with pegylated interferon α-2b plus ribavirin in the treatment of previously untreated adults (>18 years) with CHC genotype 1 and F0–F2 liver fibrosis.
A cost-consequence analysis from the Italian National Health Service (NHS) perspective using two decision tree models was carried out. We considered the TT with boceprevir in the first model and the TT with telaprevir in the second. Probabilities of each event were derived from literature and an expert panel. Direct medical costs were obtained from official sources (€2013).
In the boceprevir model, the average cost per patient starting the treatment with pegylated interferon α-2a plus ribavirin was estimated to be €21,570.06; the cost was estimated to be €22,060.00, starting the treatment with pegylated interferon α-2b plus ribavirin. In the telaprevir model, the average cost per patient starting the treatment with pegylated interferon α-2a plus ribavirin was estimated to be €24,320.35; the cost was estimated to be €25,696.43, starting the treatment with pegylated interferon α-2b plus ribavirin. The sensitivity analysis confirmed the results of the base case.
We performed a cost consequence analysis focused on the economic implications of starting the DT 4 week lead-in period either with peginterferon α-2a or α-2b and, based on the RVR status, the consequent DT or TT therapy continuation, in the therapeutic management of CHC genotype 1 patients. Regardless of the protease inhibitor administered, from the Italian NHS perspective, starting the treatment with pegylated interferon α-2a plus ribavirin is a cost-saving strategy compared with starting with pegylated interferon α-2b plus ribavirin.
- Bacon BR, Gordon SC, Lawitz E, et al (HCV RESPOND-2 Investigators). Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17. CrossRef
- Zeuzem S, Andreone P, Pol S, et al (REALIZE Study Team). Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28. CrossRef
- Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16. CrossRef
- Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206. CrossRef
- Indicazioni dell’Associazione Italiana per lo Studio del Fegato (AISF) sull’uso della triplice terapia (interferone-peghilato alfa + ribavirina + inibitore della proteasi di prima generazione) per il trattamento dei pazienti con epatite cronica da HCV genotipo 1. Documento pubblicato online in data 24 aprile 2013. http://www.webaisf.org/.
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64. CrossRef
- Nota AIFA. Istruzioni d’uso Incivo®.
- Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther. 2004;9:491–7.
- Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C intervention therapy group. Clin Pharmacol Ther. 2000;68:556–67. CrossRef
- Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276:1172–7. CrossRef
- Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13:277–88. CrossRef
- Romero-Gómez M, Planas R, Ampuero J, et al. Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C. Aliment Pharmacol Ther. 2013;37:1065–73. CrossRef
- Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22–31. CrossRef
- McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93. CrossRef
- Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon alpha-2a plus ribavirin vs peginterferon alpha-2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138:108–15. CrossRef
- Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140:459–68. CrossRef
- Study C208. An open-label study of telaprevir administered every 12 or 8 hours in combination with one of two pegylated interferons and ribavirin in treatment-naive genotype 1 chronic hepatitis C participants. ClinicalTrials.gov Identifier: NCT00528528.
- Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010;138(1):34–6. CrossRef
- http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_Product_Information/human/000280/WC500039388.pdf. Ultimo accesso luglio 2013.
- Gruppo di lavoro AIES (coordinato da G. Fattore). Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEcon Ital Res Artic. 2009;11:83–93. CrossRef
- Cammà C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56:850–60. CrossRef
- Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell’epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0–F2
PharmacoEconomics Italian Research Articles
Volume 15, Issue 3 , pp 111-122
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. Springer Healthcare Italia Srl, Via Decembrio 28, 20137, Milano, Italia
- 2. Roche S.p.A., Monza, Italia
- 3. Divisione Malattie Infettive e Tropicali, Fondazione IRCCS Ospedale San Matteo, Università di Pavia, Pavia, Italia